MASS · 908 Devices Inc.
Market Cap
$412.92M
Shares
41.33M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.04
Open$10.39
Day$9.79–10.53
52W close$5.09–11.10
Avg vol 30d486K
Short int2.8M · 6.8% float · 5.1d
Short vol61%
Last earningsAug 11, 2026
DataDec 2020–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 19, 2026
Est · unconfirmed
· in 11 wks
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$60.84M
Trailing 12 months
Net income (TTM)
−$34.66M
Trailing 12 months
Revenue growth YoY
+23.3%
Year over year
Operating margin
-64.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.2%
Year over year · more shares
Price change (1Y)
+81.9%
Trailing year
Short interest
6.8%
Latest settlement · 5.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26
TL;DR. 908 Devices posted 23% Q2 revenue growth to $16.1M, more than halved its adjusted EBITDA loss to negative $1.9M, and raised the low end of its 2026 revenue outlook to $68-70M, while reporting an $11.9M net loss from continuing operations and pulling AVCAD out of guidance.
Bullish
- + Q2 revenue grew 23% year-over-year to $16.1 million.
- + Adjusted EBITDA loss improved by more than 50% year-over-year to negative $1.9M.
- + Company raised the low end of 2026 revenue guidance to $68-70M (21-25% growth).
- + Adjusted gross margin expanded 85 basis points to 57% in Q2.
- + NearLab acquisition is ramping, with more than 35 devices sold in roughly two months post-close.
Bearish
- − Net loss from continuing operations was $11.9 million in Q2 2026.
- − AVCAD program contribution was removed from 2026 core guidance, with any contribution now upside-only.
- − Recurring revenue grew only 4% year-over-year to $4.9 million.
- − Q2 cash usage of $10.2 million included $13.5M for the NearLab acquisition.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.47
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+38%
above
Price vs 50-day avg
+13%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
82%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+21%
trailing
6-month return
+65%
trailing
YTD return
+91%
this year
Relative strength
+49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +15 funds added
Insider flow
Distributing
Net -$1.0M over 90 days · 100% sells
Short interest
Falling
6.76% of float · ▼ -17.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
111 holders — mid 3-yr range
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
+18%
Y/Y
Gross margin
51%
contracting
EPS growth
+125%
Y/Y
Free cash flow
$-24.6M
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2021
Revenue
· 2021
$41M – $43M
Guided vs delivered
· last 1 settled
Revenue
2021
guided $41M – $43M
$42.21M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+38%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
82%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +15 funds added
Insider flow
Distributing
Net -$1.0M over 90 days · 100% sells
Short interest
Falling
6.76% of float · ▼ -17.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
111 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $10 · 82%
Range high $11
vs 200-day avg +38%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MASS
this stock
908 Devices Inc.
|
$412.92M | +91.2% | +17.7% | — | 6.8% |
|
ABT
Abbott Laboratories
|
$189.18B | -13.2% | +5.7% | 30.4 | 1.2% |
|
MDT
Medtronic plc
|
$118.37B | -3.1% | +8.4% | 22.8 | 1.1% |
|
SYK
Stryker Corp
|
$118.14B | -12.4% | +11.2% | 31.9 | 1.8% |
|
BSX
Boston Scientific Corp
|
$70.10B | -50.8% | +12.5% | 19.6 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MASS | -9.6% | +21.0% | +65.4% | -5.9% | +91.2% |
| SPY | +0.3% | +0.6% | +16.7% | +0.8% | +13.4% |
| vs SPY | -9.8% | +20.4% | +48.7% | -6.7% | +77.9% |
Key facts
CIK
1555279
CUSIP
65443P102
13F (30d)
96 filings
92 filers
Visit website
Investor relations